No Data
BridgeBio Announces Publication of Case Study Exploring Portfolio Theory's Impact on Biomedical Innovation in The Journal of Portfolio Management
Leerink Partners Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
Scotiabank Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $44
Positive Outlook on BridgeBio Pharma's BBP-812 Gene Therapy: Buy Rating Reaffirmed
BridgeBio Pharma Presents Positive Data From CANaspire Phase 1/2 Study In Canavan Disease
BridgeBio Presents Positive Preliminary Data From Eleven Participants Dosed In CANaspire Phase 1/2 Clinical Trial Of BBP-812;
No Data
No Data